Bone Metastasis - Pipeline Review, H1 2014: Industry Trends and Forecast


Published on

Bone Metastasis - Pipeline Review, H1 2014 @

This report provides comprehensive information on the therapeutic development for Bone Metastasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases.

Published in: Healthcare, Business
  • Be the first to comment

  • Be the first to like this

No Downloads
Total views
On SlideShare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide

Bone Metastasis - Pipeline Review, H1 2014: Industry Trends and Forecast

  1. 1. Bone Metastasis - Pipeline Review, H1 2014 Bone Metastasis - Pipeline Review, H1 2014 Summary Global Markets Directs, Bone Metastasis - Pipeline Review, H1 2014, provides an overview of the Bone Metastasiss therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Bone Metastasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bone Metastasis and special features on late-stage and discontinued projects. Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Bone Metastasis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Bone Metastasis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Bone Metastasis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Bone Metastasis pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Bone Metastasis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Bone Metastasis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Table Of Contents table Of Contents 2 list Of Tables 7 list Of Figures 8 introduction 9 global Markets Direct Report Coverage 9 bone Metastasis Overview 10 therapeutics Development 11 pipeline Products For Bone Metastasis - Overview 11 pipeline Products For Bone Metastasis - Comparative Analysis 12 bone Metastasis - Therapeutics Under Development By Companies 13 bone Metastasis - Therapeutics Under Investigation By Universities/institutes 16 bone Metastasis - Pipeline Products Glance 17 late Stage Products 17 clinical Stage Products 18 Bone Metastasis - Pipeline Review, H1 2014
  2. 2. early Stage Products 19 bone Metastasis - Products Under Development By Companies 20 bone Metastasis - Products Under Investigation By Universities/institutes 21 bone Metastasis - Companies Involved In Therapeutics Development 22 johnson & Johnson 22 celsion Corporation 23 amgen Inc. 24 eli Lilly And Company 25 takeda Pharmaceutical Company Limited 26 sigma-tau S.p.a. 27 bayer Ag 28 medivir Ab 29 osteologix Holdings Plc. 30 transgene Sa 31 merrion Pharmaceuticals Plc 32 digna Biotech, S.l. 33 debiopharm International S.a. 34 amura Holdings Ltd. 35 alethia Biotherapeutics Inc. 36 deciphera Pharmaceuticals, Llc 37 apt Therapeutics, Inc. 38 twi Pharmaceuticals, Inc. 39 dextech Medical Ab 40 alphamab Co., Ltd 41 bone Metastasis - Therapeutics Assessment 42 assessment By Monotherapy Products 42 assessment By Combination Products 43 assessment By Target 44 assessment By Mechanism Of Action 47 assessment By Route Of Administration 50 assessment By Molecule Type 52 drug Profiles 54 denosumab - Drug Profile 54 product Description 54 mechanism Of Action 54 r&d Progress 54 denosumab - Drug Profile 57 product Description 57 mechanism Of Action 57 r&d Progress 57 radium Ra 223 Dichloride - Drug Profile 60 product Description 60 mechanism Of Action 60 r&d Progress 60 zoledronic Acid - Drug Profile 63 product Description 63 mechanism Of Action 63 r&d Progress 63 mln-1202 - Drug Profile 65 product Description 65 mechanism Of Action 65 r&d Progress 65 doxorubicin Liposomal - Drug Profile 66 product Description 66 mechanism Of Action 66 r&d Progress 66 radium Ra 223 Dichloride - Drug Profile 69 product Description 69 mechanism Of Action 69 r&d Progress 69 osteodex - Drug Profile 72 product Description 72 mechanism Of Action 72 r&d Progress 72 miv-711 - Drug Profile 73 product Description 73 mechanism Of Action 73 r&d Progress 73 Bone Metastasis - Pipeline Review, H1 2014
  3. 3. debio-0719 - Drug Profile 74 product Description 74 mechanism Of Action 74 r&d Progress 74 p-17 - Drug Profile 75 product Description 75 mechanism Of Action 75 r&d Progress 75 disitertide - Drug Profile 76 product Description 76 mechanism Of Action 76 r&d Progress 76 miv-710 - Drug Profile 78 product Description 78 mechanism Of Action 78 r&d Progress 78 sst-0001 - Drug Profile 79 product Description 79 mechanism Of Action 79 r&d Progress 79 tg-3003 - Drug Profile 80 product Description 80 mechanism Of Action 80 r&d Progress 80 ab-25e9 - Drug Profile 81 product Description 81 mechanism Of Action 81 r&d Progress 81 am-3701 - Drug Profile 82 product Description 82 mechanism Of Action 82 r&d Progress 82 dcc-2909 - Drug Profile 83 product Description 83 mechanism Of Action 83 r&d Progress 83 ac-301 - Drug Profile 84 product Description 84 mechanism Of Action 84 r&d Progress 84 apt-102 - Drug Profile 85 product Description 85 mechanism Of Action 85 r&d Progress 85 secreted Phosphoprotein 24 Kda - Drug Profile 86 product Description 86 mechanism Of Action 86 r&d Progress 86 vicrostatin - Drug Profile 87 product Description 87 mechanism Of Action 87 r&d Progress 87 adm-01 - Drug Profile 88 product Description 88 mechanism Of Action 88 r&d Progress 88 jnj-28312141 - Drug Profile 89 product Description 89 mechanism Of Action 89 r&d Progress 89 dp-6865 - Drug Profile 90 product Description 90 mechanism Of Action 90 r&d Progress 90 ly-2109761 - Drug Profile 91 product Description 91 mechanism Of Action 91 r&d Progress 91 Bone Metastasis - Pipeline Review, H1 2014
  4. 4. ly-364937 - Drug Profile 92 product Description 92 mechanism Of Action 92 r&d Progress 92 egfr Inhibitors For Oncology - Drug Profile 93 product Description 93 mechanism Of Action 93 r&d Progress 93 (paclitaxel + Peg + Alendronate) - Drug Profile 94 product Description 94 mechanism Of Action 94 r&d Progress 94 (hpma + Paclitaxel + Alendronate) - Drug Profile 95 product Description 95 mechanism Of Action 95 r&d Progress 95 nbs-101 - Drug Profile 96 product Description 96 mechanism Of Action 96 r&d Progress 96 maspin - Drug Profile 97 product Description 97 mechanism Of Action 97 r&d Progress 97 kn-013 - Drug Profile 98 product Description 98 mechanism Of Action 98 r&d Progress 98 bone Metastasis - Recent Pipeline Updates 99 bone Metastasis - Dormant Projects 127 bone Metastasis - Discontinued Products 128 bone Metastasis - Product Development Milestones 129 featured News & Press Releases 129 oct 09, 2013: Medivir: Positive Results From A Phase I Study With Miv-711 For The Treatment Of Osteoarthritis And Other Bone Related Disorders 129 oct 01, 2013: Goodwin Biotechnology Announces The Return Of Ab-25e9 Monoclonal Antibody Project From Alethia Biotherapeutics 130 jul 17, 2013: The New England Journal Of Medicine Publishes Results From The Phase Iii Alsympca Study Of Xofigo 130 jun 20, 2013: Algeta Opens Commercial Production Facility For Xofigo Injection In Kjeller, Norway 132 may 30, 2013: Algeta Announces First Sale Of Xofigo In Us 133 may 22, 2013: Celsion Receives Additional Patents Covering Thermodox Technologies 133 feb 15, 2013: Algeta Presents Further Sub-analysis Of Phase Iii Alsympca Study Of Radium-223 Dichloride At 2013 Genitourinary Cancers Symposium 134 jan 14, 2013: Us Nuclear Regulatory Commission Issues Licensing Decision For Radium-223 Dichloride 135 oct 23, 2012: Amgen's Xgeva Obtains Approval From Nice For Eligibility To Nhs Funding 135 sep 17, 2012: Bayer To Present Data On Alpharadin At Esmo 2012 Congress 136 appendix 137 methodology 137 coverage 137 secondary Research 137 primary Research 137 expert Panel Validation 137 contact Us 138 disclaimer 138 ResearchMoz( is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price. Contact: M/s Sheela, 90 State Street, Suite 700, Albany NY - 12207 United States Tel: +1-518-618-1030 USA - Canada Toll Free 866-997-4948 Email: Website: Bone Metastasis - Pipeline Review, H1 2014
  5. 5. Bone Metastasis - Pipeline Review, H1 2014